NovaBay Pharmaceuticals announced beneficial results from a Phase II clinical study of NVC-422 ophthalmic solution, used for the treatment of adenoviral conjunctivitis, a contagious ocular infection commonly known as ‘pink eye’.
The study randomised 452 patients and reportedly improved clinical signs, symptoms and microbiological findings in 38% of patients infected with adenovirus serotypes associated with epidemic kerato conjunctivitis.
The positive effect was also seen for sustained clearing of blurred vision in all patients treated with NVC-422 versus placebo.
NovaBay chairman and CEO Ron Najafi said that the trial “has generated important hypothesis as to the mechanism of action of the drug and its potential benefits for the treatment of viral conjunctivitis”.
Epidemic kerato conjunctivitis is a contagious eye infection affecting both the cornea and the conjunctiva.